• Glenn Hearson

The Efficacy and Mechanism Evaluation of Treating IPF with the addition of Co-trimoxazole

Updated: Jun 10, 2019


EME-TIPAC The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the addition of Co-trimoxazole

The lead researcher is Professor Andrew Wilson, from the EME-TIPAC research team at the University of East Anglia, with Dr Gauri Saini leading for us in Nottingham along with Lucy Howard.


What is the purpose of this trial?

Pulmonary fibrosis is a condition with limited treatments. It is thought to occur because of tiny “scars” (which we call fibrosis) that develop throughout the lungs. In a previous study, it appeared that people with pulmonary fibrosis who regularly took an antibiotic (called co-trimoxazole) were more likely to be alive after one year of the treatment than those who didn’t.

However, treatments for pulmonary fibrosis are changing and we are trying to find out if co-trimoxazole effective with these medications.

We want to know whether co-trimoxazole, when given alongside current treatments, improves life expectancy and/or reduces the chances of a person with pulmonary fibrosis being admitted to hospital.

In addition, we would like to find out how co-trimoxazole may be working so that we can use this information to develop other better treatments.

For more information contact:

lucy.howard@nottingham.ac.uk

#ipfstudy #news

Copyright Nottingham Respiratory Research Unit 2016

  • Nottingham RRU/BRC Facebook
  • Nottingham BRC Lung/NRRU Twitter

Tel: 0115-8404844